Ani Pharmaceuticals ANIP
NASDAQ ANIP
$77.18 -0.84 (-1.08%)
At close: Aug 20, 2026 · 7:09 PM UTC

Ani Pharmaceuticals (ANIP) Cash from Discontinued Operations (2012 - 2013)

Ani Pharmaceuticals (ANIP) posted Cash from Discontinued Operations of 44000.0 for Q4 2013, up 118.75% sequentially from 234624.0 in Q3 2013, and up 157.83% YoY from 17065.4 in Q4 2012.

Ani Pharmaceuticals (ANIP) Cash from Discontinued Operations (2012 - 2013) Analysis & Trends

Ani Pharmaceuticals has reported Cash from Discontinued Operations for 2 years, with the latest figure at 44000.0 in Q4 2013.

  • Quarterly Cash from Discontinued Operations rose 157.83% year-over-year to 44000.0 in Q4 2013, while the trailing twelve-month figure through Dec 2014 was 266707.0 (up 5.45% YoY) and the FY2013 annual result came in at 195000.0, down 37.32% from the prior year.
  • Cash from Discontinued Operations rose to 44000.0 in Q4 2013 per ANIP's latest filing, from 234624.0 in the prior quarter.
  • Over five years, Cash from Discontinued Operations peaked at 44000.0 in Q4 2013 and troughed at 234624.0 in Q3 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Haleon 43.89 Bn 42.93 Bn - -
2 Teva Pharmaceutical Industries 43.30 Bn 39.65 Bn 2.15 Bn -
3 Zoetis 31.45 Bn 29.77 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.58 Bn 22.78 Bn 5.10 Bn -
5 United Therapeutics 22.20 Bn 19.53 Bn 683.80 Mn -
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.50 Bn 15.11 Bn 935.80 Mn -
8 Elanco Animal Health 11.70 Bn 11.17 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.12 Bn 9.96 Bn - -
10 Ani Pharmaceuticals 1.63 Bn 1.27 Bn 165.89 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2013 44,000.00
Dec 31, 2013 44,000.00
Sep 30, 2013 -234,624.00
Sep 30, 2013 -234,624.00
Dec 31, 2012 -76,083.00
Dec 31, 2012 -76,083.00
Sep 30, 2012 -15,363.00
Sep 30, 2012 -15,363.00